In hematological malignancies, amplification of MDM2 was reported for AML, CML ALL with no concomitant mutations in exons 4–10 of the TP53 gene [106] and overexpression of MDM2 is associated with poor prognosis in AML [107]. This evidence concerns the gene MDM2 and chronic myelogenous leukemia, BCR-ABL1 positive.